Table 2.
Descriptive epidemiology of Alaska Native gastric cancer patients n (%)
| Overall | Female | Male | |
| Patients | 132 | 50 (37.9) | 82 (62.1) |
| Mean age (yr) | 59.8 ± 1.2 | 62.4 ± 2.0 | 58.2 ± 1.4 |
| Histological type | |||
| Diffuse | 75 (56.8) | 29 (58.0) | 46 (56.1) |
| Intestinal | 51 (38.6) | 16 (32.0) | 35 (42.7) |
| NOS | 6 (4.5) | 5 (10.0) | 1 (1.2) |
| Blood type | |||
| A+ | 55 (41.7) | 23 (46.0) | 32 (39.0) |
| AB+ | 8 (6.1) | 3 (6.0) | 5 (6.1) |
| B+ | 9 (6.8) | 5 (10.0) | 4 (4.9) |
| O+ | 30 (22.7) | 10 (20.0) | 20 (24.4) |
| Unknown | 30 (22.7) | 9 (18.0) | 21 (25.6) |
| Histological appearance | |||
| Signet Ring | 52 (39.4) | 23 (46.0) | 29 (35.4) |
| Adenocarcinoma | 80 (59.8) | 27 (54.0) | 53 (64.6) |
| Linitis Plastica, AC | 2 (2.5) | 0 (0) | 2 (3.8) |
| Mucinous, AC | 2 (2.5) | 0 (0) | 2 (3.8) |
| Tubular, AC | 1 (1.3) | 0 (0) | 1 (1.9) |
| Papillary | 1 (1.3) | 0 (0) | 1 (1.9) |
| NOS, AC | 75 (93.8) | 27 (100) | 46 (86.8) |
| Stage | |||
| I | 28 (21.2) | 8 (16.0) | 20 (24.4) |
| II | 24 (18.2) | 6 (12.0) | 18 (22.0) |
| III | 14 (11.4) | 4 (8.0) | 10 (12.2) |
| IV | 66 (50.0) | 32 (64.0) | 34 (41.5) |
| Grade | |||
| Well/moderately differentiated | 35 (26.5) | 9 (18.0) | 26 (31.7) |
| Poorly differentiated | 88 (66.7) | 36 (72.0) | 52 (63.4) |
| Unknown | 9 (6.8) | 5 (10.0) | 4 (4.9) |
| Anatomic site | |||
| GE JX | 12 (9.1) | 5 (10.0) | 7 (8.5) |
| Cardia | 10 (7.6) | 5 (10.0) | 5 (6.1) |
| Fundus | 12 (9.1) | 6 (12.0) | 6 (7.3) |
| Body | 33 (25.0) | 10 (20.0) | 23 (28.0) |
| Antrum | 18(13.6) | 8 (16.0) | 10 (12.2) |
| Pylorus | 17 (12.9) | 7 (14.0) | 10 (12.2) |
| Overlap (multifocal) | 27 (20.5) | 9 (18.0) | 18 (22.0) |
| Unspecified | 3 (2.3) | 0 (0) | 3 (3.7) |
| Regions of Alaska | |||
| North | 38 (28.8) | 17 (34.0) | 21 (25.6) |
| Interior | 11 (8.3) | 1 (2.0) | 10 (12.2) |
| Southwest | 40 (30.3) | 15 (30.0) | 25 (30.5) |
| Southcentral | 40 (30.3) | 17 (34.0) | 23 (28.0) |
| Southeast | 3 (2.3) | 0 (0) | 3 (3.7) |
| Treatment2 | |||
| Chemotherapy only | 40 (30.3) | 12 (24.0) | 28 (34.1) |
| Neoadjuvant | 21 (15.9) | 8 (16.0) | 13 (15.9) |
| Adjuvant | 12 (9.1) | 4 (8.0) | 8 (9.8) |
| Resection only | 12 (9.1) | 5 (10.0) | 7 (8.5) |
| Neoadjuvant, resection, adjuvant | 9 (6.8) | 3 (6.0) | 6 (7.3) |
| None | 38 (28.8) | 18 (36.0) | 20 (24.4) |
| Metastasis site1 | |||
| Omentum/peritoneium/diaphram | 27 (41.5) | 14 (43.8) | 13 (38.2) |
| Liver | 14 (21.5) | 6 (18.8) | 8 (23.5) |
| Lung | 1 (1.5) | 0 (0) | 1 (2.9) |
| Bone | 2 (3.1) | 0 (0) | 2 (5.9) |
| Ovary | 6 (9.2) | 6 (18.8) | 0 (0) |
| Multiple Sites | 15 (23.1) | 6 (18.8) | 10 (29.4) |
| Additional clinical and pathological variables | |||
| H. pylori | 52 (41.3) | 20 (41.7) | 32 (41.0) |
| Chronic gastritis | 101 (76.5) | 38 (76.0) | 63 (76.8) |
| GERD | 51 (39.5) | 18 (36.0) | 33 (41.3) |
| Gastric ulcer | 91 (68.9) | 35 (70.0) | 56 (68.3) |
| Tobacco | 108 (81.8) | 36 (72.0) | 72 (87.8) |
| Family history GI cancer | 38 (28.8) | 16 (32.0) | 21 (25.6) |
1
Patients with stage 4 gastric cancer were used for analysis;
2
Neoadjuvant and adjuvant treatments include chemotherapy and chemoradiation regimens based on NCCN guidelines. NOS: Not otherwise specified; AC: Adenocarcinoma; GE JX: Gastroesophageal junction; H. pylori: Helicobacter pylori; GERD: Gastroesophageal reflux disease; GC: Gastric cancer.